1000 results about "Metabolic disease" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention provides a risk prediction method and system for cardiovascular and metabolic diseases. The method comprises the following steps: collecting continuous cardiovascular-metabolism time sequence data, and extracting phase delay parameters to construct a lipid transport rhythm out-of-synchronization characteristic spectrum; quantifying the topological connection strength of the gene cluster based on the three-dimensional genome interaction strength matrix, and generating a genetic prediction model; a vascular endothelial metabolism buffer attenuation trajectory is calculated through simulation, and a critical environment exposure parameter is determined by matching a genetic instability threshold value; and fusing multi-source data to construct a dynamic toughness model, calculating a phase space shrinkage rate of a vascular metabolism steady-state boundary, and triggering graded early warning. According to the technical scheme provided by the invention, ultra-early warning of cardiovascular metabolism risks is realized, and the individual intervention target spot recognition precision is improved.

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

The invention relates to the technical field of health management of old people, and discloses a method and a system for predicting multiple diseases of old people. The method comprises the following steps: acquiring multi-modal health monitoring data of a target old person in a preset time period, wherein the multi-modal health monitoring data comprises physiological index time sequence data, a medication record sequence and a daily activity ability evaluation result; and performing cross-modal correlation analysis on the multi-modal health monitoring data to generate a disease interaction characteristic matrix containing metabolic disease correlation degree, circulatory system disease coordination index and neurodegenerative disease progress rate. And performing hierarchical clustering processing on the feature matrix by adopting a dynamic weight distribution algorithm, and outputting potential common disease combinations of the target old people and a priority score of each common disease combination. And generating a personalized intervention strategy set including a drug interaction avoidance scheme, a rehabilitation training intensity adjustment scheme and a nutrition intake ratio scheme according to the priority score.

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The present invention relates to a compound having a structure represented by formula (I) and having GLP-1 receptor agonistic activity; and the use of said compound and a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof in the preparation of a GLP-1 receptor agonist and in the preparation of a drug for treating and / or preventing metabolic diseases.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The present disclosure provides isolated Lactobacillus crispatus, a composition comprising the same, and uses thereof, which can be used to treat, prevent, alleviate or alleviate liver and kidney diseases, metabolic diseases, and the like.

The invention discloses a method and system for screening drug targets with space-time specificity and computer equipment, and relates to the technical field of bioinformatics and computational biology. The screening method is based on single cell transcriptome sequencing data, and comprises the following steps: (1) quantitatively reconstructing spatial positioning and functional modes of cells in tissues, namely 1.1) carrying out data preprocessing on the single cell transcriptome sequencing data; 1.2) reconstructing the spatial positioning of the single cell; 1.3) reconstructing a single cell biological function mode; (2) screening a drug target with space-time specificity, wherein the screening comprises the following steps: 2.1) cell-cell communication analysis; the invention discloses a single-cell data analysis method based on a GRN (Gene Regulatory Network), which is characterized by comprising the following steps of (1) establishing a single-cell data analysis method, (2) establishing a GRN (Gene Regulatory Network) taking a specific tissue microenvironment state as a core, and (3) discovering a target spot. The single-cell data analysis method is innovative, provides a new thought and a technical path for research and development of drugs for metabolic diseases and other systemic diseases, and has a popularization and application basis.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition with a glycolipid metabolism regulating effect and a preparation method and application thereof. The traditional Chinese medicine composition with the glucolipid metabolism regulating effect is prepared from the following raw materials in parts by weight: 10 to 15 parts of herba cepbalanoplosis segeti, 7 to 12 parts of fructus phyllanthi, 10 to 15 parts of fructus citri sarcodactylis and 15 to 20 parts of semen cassiae. The traditional Chinese medicine composition disclosed by the invention can be used for carrying out comprehensive and integrated prevention and control and overall regulation on glycolipid metabolic diseases, is good in treatment effect, is natural medicines, and has few side effects.

A GLP-1R agonist compound and the use thereof, specifically a compound represented by formula Ⅰ, or an isotope marker, a stereoisomer or a pharmaceutically acceptable salt thereof, and the use thereof as a drug. The compound shows a good agonistic effect and pharmacodynamic property on GLP-1R, can be used as a regulator for preparing a drug for treating, ameliorating or preventing metabolic diseases and related diseases, and has broad application prospects.

The present application relates to the field of biomedicine, and specifically provides an acylated human insulin analogue, a pharmaceutical composition thereof and a preparation method therefor, and a method for using the acylated human insulin analogue or the pharmaceutical composition thereof to treat metabolic diseases.

Aspects of the present disclosure provide engineered induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cells (EiMSCs) that exhibit persistent transgene expression. Persistent transgene expression may be achieved through use of an engineered chromatin opening sequence (ECOS). The engineered EiMSCs of the present disclosure can comprise a therapeutic polypeptide comprising one or more cytokines for the treatment of a metabolic disease, a proliferative disease, an autoimmune disease, a neurological disease, or any combination thereof.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention discloses a double-chamber micro-fluidic organ chip, a preparation method and application, and belongs to the technical field of biological materials. The double-chamber micro-fluidic organ chip sequentially comprises a top layer, an upper layer, a middle layer and a lower layer from top to bottom, cavities are formed in the upper layer and the lower layer, and micropore arrays for accommodating biological samples are arranged in the cavities; the chip further comprises a plurality of circulation channels which can be respectively communicated with the upper layer chamber and the lower layer chamber, so that a biological sample enters and exits from the micropore array; and the middle layer is a semi-permeable porous membrane. The micro-fluidic organ chip can be used for establishing a metabolic disease model, promoting interaction between organs and realizing space-time dynamic change analysis of tissues and organs.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention relates to the technical field of polypeptide drugs for metabolic diseases, in particular to a glucagon-like peptide (GLP-1), a glucose-dependent insulinotropic polypeptide (GIP) and a glucagon (GCG) triple receptor agonist (protein). According to the triple receptor agonist protein provided by the technical scheme, weight reduction is achieved, meanwhile, lower side effects are shown, and drug compliance is enhanced. The triple receptor stimulant researched and developed by the technical scheme can be applied to preparation of medicines with the effects of losing weight, reducing lipid or reducing blood sugar, solves the technical problem that the existing GLP-1, GIP and GCG triple receptor stimulants are difficult to reduce side effects while reducing body weight, and breaks through the weight loss mode that the traditional medicines depend on appetite suppression; due to the unique action mechanism and good safety, a safer and more effective treatment scheme is provided for patients, and the medicine has wide market prospects and social benefits.

The invention relates to the technical field of medical health data processing, in particular to a monitoring method, system and device for an endocrine metabolic disease patient, and the method comprises the steps: obtaining blood glucose data and other-dimension physiological data of the patient, a blood glucose standard data set and standard physiological data; screening all moments to obtain a blood sugar peak moment according to the difference between the blood sugar data distribution of each moment and the adjacent moment in the time neighborhood range; according to the blood glucose data distribution condition of each blood glucose peak moment and the rising and falling trend of the blood glucose data along with time change, the initial abnormal degree of the current moment is obtained in combination with the blood glucose change rate; according to the number of the blood sugar peak moments, the initial abnormal degree is adjusted in combination with physiological data of other dimensions of the patient and standard physiological data, the comprehensive abnormal degree of the current moment is obtained, and the monitoring result of the patient is determined based on the comprehensive abnormal degree. According to the invention, a more accurate data exception monitoring result can be obtained.

The disclosure relates to synthetic peptides that are capable of modulating metabolism and find uses e.g. in treating metabolic diseases or disorders.

The invention relates to the technical field of medical information management, and discloses a method for constructing a model for predicting glycolipid metabolic disease based on artificial intelligence, which comprises the following steps: identifying the syndrome type and pathological product of a patient with glycolipid metabolic disease, and constructing a risk identification model of the patient with glycolipid metabolic disease according to the syndrome type and pathological product; identifying the disease site, syndrome and disease factors of the glycolipid metabolic disease patient, and analyzing the disease course distribution condition of the glycolipid metabolic disease patient; according to the disease course distribution condition, determining the distinguishing capability of the risk identification model, and executing model optimization processing of the risk identification model to obtain an optimization model; when the optimization processing result meets a preset effect, outputting a feedback result of the glycolipid metabolic disease patient, and setting a result paraphrase of the feedback result; and in combination with the risk identification model, the optimization model and the result paraphrasing, performing model construction processing of the glycolipid metabolic disease patient to obtain a model construction result. According to the invention, the accuracy and reliability of glycolipid metabolic disease prediction can be improved.

The invention discloses a saussurea involucrata culture as well as a preparation method and application thereof, and belongs to the technical field of bioengineering and medicines. The invention relates to a saussurea involucrata culture, in particular to a selenium-rich and chromium-rich saussurea involucrata cell culture with DPP-IV inhibitory activity. The content of selenium in the saussurea involucrata culture reaches 200 mg / Kg dry weight or above, and the content of chromium Cr < 3 + > reaches 20 mg / Kg dry weight or above; in addition, chromium Cr < 6 + > is not detected, and the 70% ethanol extract of the saussurea involucrata cell culture is applied to an in-vitro DPP-IV inhibition test, and the inhibition rate of the 70% ethanol extract of the saussurea involucrata cell culture reaches 99.08%. The selenium-rich and chromium-rich saussurea involucrata culture with the high DPP-IV inhibition rate can be widely applied to preparation of medicines, health foods or functional foods for preventing and / or treating type 2 diabetes, obesity and related metabolic diseases.

The present application provides a pyrimidineamine compound, characterized in that the pyrimidineamine compound is a compound represented by Formula I, or its stereoisomer, tautomer, isotope derivative, hydrate, solvate, prodrug, and pharmaceutically acceptable salt. The pyrimidineamine compound described in the present application has excellent NUAK1 / NUAK2 kinase inhibitory activity and can be used for preventing or treating the following diseases by inhibiting NUAK1 / NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrosis diseases, and skin fibrosis diseases. #imgabs0#

Provided are a Parabacteroides strain, a culture, a microbial agent and the use thereof. Specifically provided is a Parabacteroides strain, which can be a strain having a deposit number of GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or a strain having at least 87% average nucleotide identity to the genome of the strain. The strain or a product based on the strain has good effects in terms of preventing or treating tumors or cancers, metabolic diseases, inflammation or autoimmune diseases, infectious diseases and central nervous system diseases.

The invention discloses application of 2-hydroxybutyric acid and derivatives thereof in preparation of drugs for preventing and / or treating metabolic diseases, and belongs to the technical field of biological medicines. Experiments prove that the 2-hydroxybutyric acid and the derivatives thereof can effectively inhibit obesity induced by high fat diet and reduce body fat, and have good improvement effects on related glucose and lipid metabolism disorders, including reduction of fasting blood-glucose, improvement of glucose tolerance, reduction of liver lipid deposition and improvement of liver functions. More importantly, the 2-hydroxybutyric acid does not affect ingestion, the metabolism improvement effect of the 2-hydroxybutyric acid depends on activation of fat heat production, and energy consumption can be directly promoted, so that obvious gastrointestinal tract adverse reactions cannot be generated, and potential mental side effects of existing appetite inhibiting drugs do not exist.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.